Skip to the page

Data / Drug companies / Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc.: 63 products in the FDA NDC directory, labeler code 50458

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Janssen Pharmaceuticals, Inc. (labeler code 50458) lists 63 products in the FDA National Drug Code Directory, covering 13 finished drugs by generic name. By type: 63 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on December 1, 2021.

The request: Watch Janssen Pharmaceuticals, Inc. (FDA labeler code 50458): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
50458
Products in commercial distribution
63
Packages
86
Finished drugs by generic name
13
Prescription products
63
Over the counter products
0
Controlled substance products
Schedule II 4, Schedule III 1
Flagged as original packager
45 of 45 products that carry the flag
Started marketing in the last 12 months
0
Products with a marketing end date set
3
Earliest marketing start
September 11, 1992
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)63100%

Products by type

TypeProductsShare
Prescription drugs63100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Risperidone1643
Paliperidone palmitate112
Canagliflozin and metformin hydrochloride81
Rivaroxaban624
Topiramate656
Paliperidone419
Methylphenidate hydrochloride439
Canagliflozin23
Ponesimod22
Mebendazole11
Pentosan polysulfate sodium11
Esketamine hydrochloride11
Itraconazole114

Dosage forms

Dosage formProductsShare
Tablet, film coated1117.5%
Tablet, extended release812.7%
Injection, suspension, extended release69.5%
Kit69.5%
Tablet, orally disintegrating57.9%
Tablet57.9%
Injection57.9%
Tablet, coated46.3%
Tablet, film coated, extended release46.3%
Solution34.8%
Capsule, coated pellets23.2%
Tablet, chewable11.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Xarelto50458-575Granule, for suspensionNew drug applications (NDA)December 1, 2021
Invega hafyera50458-612Injection, suspension, extended releaseNew drug applications (NDA)August 30, 2021
Invega hafyera50458-611Injection, suspension, extended releaseNew drug applications (NDA)August 30, 2021
Ponvory50458-720Tablet, film coatedNew drug applications (NDA)March 18, 2021
Ponvory50458-707KitNew drug applications (NDA)March 18, 2021
Spravato50458-028SolutionNew drug applications (NDA)March 5, 2019
Xarelto50458-577Tablet, film coatedNew drug applications (NDA)October 9, 2018
Vermox50458-675Tablet, chewableNew drug applications (NDA)October 20, 2016
Invokamet xr50458-943Tablet, film coated, extended releaseNew drug applications (NDA)September 20, 2016
Invokamet xr50458-942Tablet, film coated, extended releaseNew drug applications (NDA)September 20, 2016
Invokamet xr50458-941Tablet, film coated, extended releaseNew drug applications (NDA)September 20, 2016
Invokamet xr50458-940Tablet, film coated, extended releaseNew drug applications (NDA)September 20, 2016
Invega trinza50458-609Injection, suspension, extended releaseNew drug applications (NDA)May 19, 2015
Invega trinza50458-608Injection, suspension, extended releaseNew drug applications (NDA)May 19, 2015
Invega trinza50458-607Injection, suspension, extended releaseNew drug applications (NDA)May 19, 2015
Invega trinza50458-606Injection, suspension, extended releaseNew drug applications (NDA)May 19, 2015
Xarelto50458-584KitNew drug applications (NDA)September 16, 2014
Invokamet50458-543Tablet, film coatedNew drug applications (NDA)August 8, 2014
Invokamet50458-542Tablet, film coatedNew drug applications (NDA)August 8, 2014
Invokamet50458-541Tablet, film coatedNew drug applications (NDA)August 8, 2014
Invokamet50458-540Tablet, film coatedNew drug applications (NDA)August 8, 2014
Invokana50458-141Tablet, film coatedNew drug applications (NDA)March 29, 2013
Invokana50458-140Tablet, film coatedNew drug applications (NDA)March 29, 2013
Xarelto50458-579Tablet, film coatedNew drug applications (NDA)November 5, 2011
Xarelto50458-578Tablet, film coatedNew drug applications (NDA)November 4, 2011

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.